These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24849042)

  • 21. Neutralizing antibodies against adeno-associated viruses in Sjögren's patients: implications for gene therapy.
    Corden A; Handelman B; Yin H; Cotrim A; Alevizos I; Chiorini JA
    Gene Ther; 2017 Apr; 24(4):241-244. PubMed ID: 28150697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Schwann cell targeting via intrasciatic injection of AAV8 as gene therapy strategy for peripheral nerve regeneration.
    Homs J; Ariza L; Pagès G; Udina E; Navarro X; Chillón M; Bosch A
    Gene Ther; 2011 Jun; 18(6):622-30. PubMed ID: 21326330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies.
    Ito M; Takino N; Nomura T; Kan A; Muramatsu SI
    Sci Rep; 2021 Apr; 11(1):9322. PubMed ID: 33927271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophilia.
    Pabinger I; Ayash-Rashkovsky M; Escobar M; Konkle BA; Mingot-Castellano ME; Mullins ES; Negrier C; Pan L; Rajavel K; Yan B; Chapin J
    Gene Ther; 2024 May; 31(5-6):273-284. PubMed ID: 38355967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals.
    Mimuro J; Mizukami H; Shima M; Matsushita T; Taki M; Muto S; Higasa S; Sakai M; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
    J Med Virol; 2014 Nov; 86(11):1990-7. PubMed ID: 24136735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular Dystrophy.
    Verma S; Nwosu SN; Razdan R; Upadhyayula SR; Phan HC; Koroma AA; Leguizamo I; Correa NS; Kuipa M; Lee D; Vanderford TH; Gardner MR
    Hum Gene Ther; 2023 May; 34(9-10):430-438. PubMed ID: 36324212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A.
    Klamroth R; Hayes G; Andreeva T; Gregg K; Suzuki T; Mitha IH; Hardesty B; Shima M; Pollock T; Slev P; Oldenburg J; Ozelo MC; Stieltjes N; Castet SM; Mahlangu J; Peyvandi F; Kazmi R; Schved JF; Leavitt AD; Callaghan M; Pan-Petesch B; Quon DV; Andrews J; Trinh A; Li M; Wong WY
    Hum Gene Ther; 2022 Apr; 33(7-8):432-441. PubMed ID: 35156839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced transduction of mouse salivary glands with AAV5-based vectors.
    Katano H; Kok MR; Cotrim AP; Yamano S; Schmidt M; Afione S; Baum BJ; Chiorini JA
    Gene Ther; 2006 Apr; 13(7):594-601. PubMed ID: 16341060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficient removal of antibodies to adeno-associated viruses by immunoadsorption.
    Boedecker-Lips S; Judel A; Holtz S; Mayer M; Klimpke P; Kraus D; Schreiner T; Gerstmayer B; Eulitz K; Mayer MC; Weinmann-Menke J
    J Clin Apher; 2023 Oct; 38(5):590-601. PubMed ID: 37415533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5
    Majowicz A; Salas D; Zabaleta N; Rodríguez-Garcia E; González-Aseguinolaza G; Petry H; Ferreira V
    Mol Ther; 2017 Aug; 25(8):1831-1842. PubMed ID: 28596114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of Pre-Existing Neutralizing Antibodies Against Adeno-Associated Virus Serotypes 1, 2, 5, 6, 8, and 9 in Sera of Different Pig Strains.
    Dai Y; Kavita U; Lampen MH; Gielen S; Banks G; Levesque P; Kozhich A; Pillutla R; Zhang Y; Jawa V; Adam L
    Hum Gene Ther; 2022 Apr; 33(7-8):451-459. PubMed ID: 34913759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain.
    Broekman ML; Comer LA; Hyman BT; Sena-Esteves M
    Neuroscience; 2006; 138(2):501-10. PubMed ID: 16414198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adeno-associated virus antibody profiles in newborns, children, and adolescents.
    Calcedo R; Morizono H; Wang L; McCarter R; He J; Jones D; Batshaw ML; Wilson JM
    Clin Vaccine Immunol; 2011 Sep; 18(9):1586-8. PubMed ID: 21775517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.
    Gao GP; Alvira MR; Wang L; Calcedo R; Johnston J; Wilson JM
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11854-9. PubMed ID: 12192090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans.
    Ellsworth JL; O'Callaghan M; Rubin H; Seymour A
    Hum Gene Ther Clin Dev; 2018 Mar; 29(1):60-67. PubMed ID: 29624457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.
    Scallan CD; Jiang H; Liu T; Patarroyo-White S; Sommer JM; Zhou S; Couto LB; Pierce GF
    Blood; 2006 Mar; 107(5):1810-7. PubMed ID: 16249376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of adeno-associated virus neutralizing antibody activity for clinical application.
    Wang M; Crosby A; Hastie E; Samulski JJ; McPhee S; Joshua G; Samulski RJ; Li C
    Gene Ther; 2015 Dec; 22(12):984-92. PubMed ID: 26125606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AAV Infection: Protection from Cancer.
    Srivastava A; Carter BJ
    Hum Gene Ther; 2017 Apr; 28(4):323-327. PubMed ID: 27832705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy.
    Chen J; Wu Q; Yang P; Hsu HC; Mountz JD
    Mol Ther; 2006 Feb; 13(2):260-9. PubMed ID: 16324888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines.
    Lin J; Calcedo R; Vandenberghe LH; Figueredo JM; Wilson JM
    Hum Gene Ther; 2008 Jul; 19(7):663-9. PubMed ID: 18549307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.